Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.

Abstract

Purine analogues like fludarabine have been shown to be superior to conventional therapy for B-cell chronic lymphocytic leukemia (B-CLL). In order to improve the activity of fludarabine, we tested its combination with loxoribine, a guanine ribonucleotide derivative, known to enhance the sensitivity of B-CLL cells to cytotoxic drugs. B-CLL cells from 6 patients were studied; co-incubation with loxoribine 100 microM increased the activity of fludarabine by 12% to 48%, as demonstrated by XTT colorimetric assay; while 1000 microM loxoribine exerted a protective effect. Accordingly, fludarabine-induced apoptosis was enhanced by the addition of loxoribine 1000 microM (39% increase). These results indicate that the combination of loxoribine and fludarabine could be of interest in B-CLL.

• Authors: P Tosi, P L Zinzani, A Pellacani, E Ottaviani, M Magagnoli, S Tura
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 26 Issue 3-4 Pg. 343-8 (Jul 1997) ISSN: 1042-8194 [Print] United States
• PMID: 9322897 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Guanosine
• loxoribine
• Vidarabine
• fludarabine

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (pharmacology)
• Apoptosis (drug effects)
• Cell Cycle (drug effects)
• Drug Interactions
• Drug Screening Assays, Antitumor
• Female
• Guanosine (administration & dosage, analogs & derivatives)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, pathology)
• Male
• Middle Aged
• Tumor Cells, Cultured
• Vidarabine (administration & dosage, analogs & derivatives)